Regular Blood Work After Gene Therapy Warranted by Rare Condition
Recipients of certain adeno-associated virus (AAV) vector-based gene therapies should be monitored closely for signs of thrombotic microangiopathy (TMA), FDA advisors agreed. “Frequent laboratory assessments are necessary,” said Barry Byrne, MD, PhD, of the University of Florida in Gainesville, based on his observations that patients on onasemnogene abeparvovec (Zolgensma) tend to first show IgM presence […]